ABOUT EVENT

Welcome to the 14th World Clinical Biomarkers & CDx Summit!

The 14th World Clinical Biomarkers & Companion Diagnostics Summit was the premier four-day forum dedicated to advancing biomarker research and companion diagnostics. Gathering leading biopharma, academia, service and solution providers, this meeting fostered meaningful conversations around the industry’s latest developments, regulatory changes, and innovative strategies.

Three days of comprehensive data-driven sessions, panel discussions, and networking opportunities explored key topics such as:

  • The impact of global regulatory frameworks
  • Advancements in precision oncology
  • The integration of AI and digital pathology

Attendees gained insights into patient-centric approaches and the importance of equitable access to precision medicine, knowledge-share, and collaborate to drive innovation and improve patient outcomes in clinical biomarkers and companion diagnostics.

Ensure you’re positioned at the forefront of this rapid-evolving field by joining the pre-conference thought leadership workshops hosted by our partners Foundation Medicine, Roche, Quest Diagnostics, and Guardant.

What You Missed:

attendees

500+
Attendees

speakers

50+
Biopharma Speakers

companies

30+
New Companies

network

13+
Hours of In-Person Networking

2024 Attendees:

31633 - Logo Banners (1)

A Snapshot of 2024 Hot Sessions:

Day 1:

Unleashing the Power of Digital Pathology & AI to Accelerate Drug Development Across All Therapeutic Areas

Michael Montalto, Vice President – Precision Medicine, Amgen

Amgen-removebg-preview

Bringing the First Precision Medicine to Treat CNS Diseases using Innovative Biomarker Discovery Platforms

Wen Luo, Chief Executive Officer/Chief Scientific Officer, Denovo Biopharma LLC

Denova_Biopharma-removebg-preview

Advancing Precision Medicine in Early Bladder Cancer with Urine Assay Technology

David Weingeist, Scientific Director, Oncology Precision Medicine & Diagnostics, Johnson & Johnson

JOhnson___Johnson-removebg-preview

Day 2:

Integrating the Patient Perspective in Clinical Biomarker Development & Companion Diagnostics for Enhanced Patient

Ann Fish-Steagall, Senior Vice President - Patient Services, LUNGevity Foundation

LUNGevity-removebg-preview

Leveraging MRD to Develop Personalized Treatment Options

Duane Hassane, Senior Director - Head of Translational Omics, Haematology R&D, AstraZeneca

AstraZeneca-removebg-preview

Developing & Executing Proof of Mechanism Strategies to Increase the Speed and Quality of Decision Making

Amanda Wang, Vice President, Head of Translational Science Leader Hub, Bayer Science

Bayer_Sciences-removebg-preview

Day 3:

Leveraging Effective Communication Strategies to Enhance Stakeholder Engagement in Clinical Biomarker Development

Sharon Moulis, Senior Director - Precision Medicine and Companion Diagnostics, Pfizer

pfizer-removebg-preview

Navigating the Complexity of Integrating Companion Diagnostic Development & Large-Scale Patient Screening into Late Phase Oncology Drug Development

Diarmuid Moran, Head of Precision Medicine and Diagnostics, Astellas Innovation Management LLC

Astellas_Pharma-removebg-preview

Catalyzing Global Breakthroughs with Strategic Partnerships & Patient-Centric Precision Medicine for a Healthier Future

Flora Berisha, Global Head of Diagnostics Partnering & Development, Precision Medicine, Johnson & Johnson Services, Inc

JOhnson___Johnson-removebg-preview